
A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia‐chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria
We conducted a phase II study to evaluate the efficacy and safety of dasatinib in Japanese patients with imatinib‐resistant or imatinib‐intolerant chronic myeloid leukemia (CML).
No References
No Citations
No Supplementary Data
No Article Media
No Metrics
Keywords: European LeukemiaNet 2013 recommendations; chronic myeloid leukemia; dasatinib; major molecular response; molecular response ≧4.5 log reduction
Document Type: Research Article
Publication date: December 1, 2015